PRE 14A - Bowen Acquisition Corp (0001973056) (Filer)
8-K - Bowen Acquisition Corp (0001973056) (Filer)
NT 10-Q - Bowen Acquisition Corp (0001973056) (Filer)
SCHEDULE 13G/A - Bowen Acquisition Corp (0001973056) (Subject)
SCHEDULE 13G - Bowen Acquisition Corp (0001973056) (Subject)
SCHEDULE 13G/A - Bowen Acquisition Corp (0001973056) (Subject)
10-K - Bowen Acquisition Corp (0001973056) (Filer)
8-K - Bowen Acquisition Corp (0001973056) (Filer)
NT 10-K - Bowen Acquisition Corp (0001973056) (Filer)
DEF 14A - Bowen Acquisition Corp (0001973056) (Filer)
4 - Bowen Acquisition Corp (0001973056) (Issuer)
4 - Bowen Acquisition Corp (0001973056) (Issuer)
4 - Bowen Acquisition Corp (0001973056) (Issuer)
4 - Bowen Acquisition Corp (0001973056) (Issuer)
4 - Bowen Acquisition Corp (0001973056) (Issuer)
4 - Bowen Acquisition Corp (0001973056) (Issuer)
4 - Bowen Acquisition Corp (0001973056) (Issuer)
4 - Bowen Acquisition Corp (0001973056) (Issuer)
3 - Bowen Acquisition Corp (0001973056) (Issuer)
4 - Bowen Acquisition Corp (0001973056) (Issuer)
SC 13G - Bowen Acquisition Corp (0001973056) (Subject)
SC 13G - Bowen Acquisition Corp (0001973056) (Subject)
SC 13G/A - Bowen Acquisition Corp (0001973056) (Subject)
SC 13G/A - Bowen Acquisition Corp (0001973056) (Subject)
SC 13G/A - Bowen Acquisition Corp (0001973056) (Subject)
New York, NY, May 29, 2025 (GLOBE NEWSWIRE) -- Bowen Acquisition Corp (NASDAQ:BOWN) ("BOWN"), a special purpose acquisition company, announced that on May 28, 2025, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("NASDAQ") advising the Company that the Company does not comply with NASDAQ's Listing Rule 5250(c)(1) for continued listing because NASDAQ has not received the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 (the "Form 10-Q"). NASDAQ has informed the Company that it has until July 28, 2025 to submit a plan to regain compliance with respect to this delinquent report. If NASDAQ approves the Company's pla
New York, NY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bowen Acquisition Corp (NASDAQ:BOWN) ("BOWN"), a special purpose acquisition company, announced the execution of an agreement and plan of merger (the "Merger Agreement") with Shenzhen Qianzhi BioTechnology Co., Ltd ("Qianzhi BioTech"), a biotech company engaged in development, manufacturing and sales of ozonated health and wellness products in China. Pursuant to the Merger Agreement, BOWN's wholly owned subsidiary, Bowen Merger Sub, a Cayman Islands exempted company, will merge (the "Merger" or the "Business Combination") with and into Qianzhi Group Holding (Cayman) Limited, parent of Qianzhi BioTech and an exempted company incorporated with